Immunological and virological factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection

被引:16
|
作者
García, F [1 ]
Plana, M [1 ]
Mestre, G [1 ]
Arnedo, M [1 ]
Gil, C [1 ]
Miró, JM [1 ]
Cruceta, A [1 ]
Pumarola, T [1 ]
Gallart, T [1 ]
Gatell, JM [1 ]
机构
[1] Univ Barcelona, Infect Dis Unit,Hosp Clin, Inst Invest Biomed August Pi Sunyer DIDBAPS, Clin Inst Infect & Immunol,Fac Med, E-08036 Barcelona, Spain
关键词
STI; chronic HIV; infection; predictive factors;
D O I
10.1097/00002030-200209060-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The objective was to analyse which baseline factors could predict a favourable outcome after structured therapy interruption (STI). Methods: Data of three Spanish pilot studies of STI in early stage chronic HIV-1-infected patients were analysed. A set of 37 variables at baseline was used. Plasma and tonsillar tissue viral load (VL), lymphocyte immunophenotyping and proliferative responses (LPR) to mitogens and specific antigens, and HIV-1 specific cytotoxic T lymphocyte responses were assessed at baseline. Response was defined as a VL set-point after 6 months off antiretroviral therapy after the last interruption of < 5000 copies/ml and 0.5 log(10) below baseline PVL before any antiretroviral therapy. Results: After STI, the 44 patients were classified as follows: 18 (41%) as responders, 26 (59%) as non-responders. In the univariate analysis patients who responded had a significantly lower baseline level of CD4CD38 (P=0.0068) and naive CD4 T cells (P=0.03), and a higher level of memory CD4 T cells (P=0.03) and proliferative response to tetanus toxoid (TT) (P=0.01) and HIV-1 p24 (P=0.03) than non-responders. A model incorporating five qualitative variables transformed according to the median value (CD4CD38, CD4 naive and memory T cells and stimulation index to TT and HIV-1 p24) at baseline could classify 97% of patients correctly (P=0.0001). Conclusions: A level of memory CD4 T cells and proliferative response to recall antigens above the median may predict a good response to STI, suggesting that preserved memory response in CD4 T cells is important factor. (C) 2002 Lippincott Williams & Wilkins.
引用
收藏
页码:1761 / 1765
页数:5
相关论文
共 50 条
  • [41] No Significant Effect of COVID-19 on Immunological and Virological Parameters in Patients With HIV-1 Infection
    Calza, Leonardo
    Bon, Isabella
    Borderi, Marco
    Colangeli, Vincenzo
    Viale, Pierluigi
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (01) : E6 - E8
  • [42] New model for HIV-1 infection may alter therapy
    Larkin, M
    LANCET, 1996, 348 (9041): : 1574 - 1574
  • [43] Prevention of HIV-1 Infection with Early Antiretroviral Therapy
    Cohen, Myron S.
    Chen, Ying Q.
    McCauley, Marybeth
    Gamble, Theresa
    Hosseinipour, Mina C.
    Kumarasamy, Nagalingeswaran
    Hakim, James G.
    Kumwenda, Johnstone
    Grinsztejn, Beatriz
    Pilotto, Jose H. S.
    Godbole, Sheela V.
    Mehendale, Sanjay
    Chariyalertsak, Suwat
    Santos, Breno R.
    Mayer, Kenneth H.
    Hoffman, Irving F.
    Eshleman, Susan H.
    Piwowar-Manning, Estelle
    Wang, Lei
    Makhema, Joseph
    Mills, Lisa A.
    de Bruyn, Guy
    Sanne, Ian
    Eron, Joseph
    Gallant, Joel
    Havlir, Diane
    Swindells, Susan
    Ribaudo, Heather
    Elharrar, Vanessa
    Burns, David
    Taha, Taha E.
    Nielsen-Saines, Karin
    Celentano, David
    Essex, Max
    Fleming, Thomas R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (06): : 493 - 505
  • [44] HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally infected child
    Frange, Pierre
    Faye, Albert
    Avettand-Fenoel, Veronique
    Bellaton, Erainna
    Deschamps, Diane
    Angin, Mathieu
    Caillat-Zucman, Sophie
    Peytavin, Gilles
    Le Chenadec, Jerome
    Warszawski, Josiane
    Rouzioux, Christine
    Saez-Cirion, Asier
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [45] Immunological and virological effects of highly active antiretroviral therapy in two HIV-1 infected children
    Leon, JA
    Leal, M
    Lissen, E
    Gurbindo, D
    Muñoz-Fernández, MA
    ACTA PAEDIATRICA, 2000, 89 (03) : 373 - 374
  • [46] HIV-1 Subtype and Virological Response to Antiretroviral Therapy: Acquired Drug Resistance
    Soares, Esmeralda A.
    Santos, Andre F.
    Soares, Marcelo A.
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (05) : 738 - 738
  • [47] HIV-1-AG AS THE ONE MARKER IN THE EARLY STAGE OF HIV-1 INFECTION
    SOTO, B
    REY, C
    PINEDA, J
    AGUADO, I
    LEAL, M
    LISSEN, E
    VOX SANGUINIS, 1991, 60 (04) : 241 - 241
  • [48] Early antiretroviral therapy reduces HIV-1 DNA following perinatal HIV-1 infection
    Foster, C.
    Kaye, S.
    Fidler, S.
    Pace, M.
    Jones, M.
    Hopkins, E.
    Robinson, N.
    Frater, J.
    HIV MEDICINE, 2015, 16 : 6 - 6
  • [49] A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection
    Cardiello, PG
    Hassink, E
    Ananworanich, J
    Srasuebkul, P
    Samor, T
    Mahanontharit, A
    Ruxrungtham, K
    Hirschel, B
    Lange, J
    Phanuphak, P
    Cooper, DA
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (04) : 594 - 600
  • [50] Investigation of HIV-1 evolution following early therapy in patients with primary HIV-1 infection
    Huckett, L
    Devereux, H
    Loveday, C
    Kinloch, S
    Janossy, G
    AIDS, 1998, 12 : S22 - S22